B+
Bull case
25%
Probability
Target price
$10.50
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
EOLS
EvolusCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Raised guidance, 21% Q2 revenue growth and a third consecutive quarter of positive adjusted EBITDA support a constructive commercial thesis if Evolysse uptake persists and Jeuveau promotion is remediated without broader disruption. [#SEC-8K-2026-08-05]
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.5.
What can break
FDA-requested Jeuveau promotional remediation could constrain marketing or create further compliance costs; the response and any subsequent action are not yet known. FDA letter
Momentum
70
Value
41
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $8.00 · Bull $10.50 · Bear $5.30Analysis 2026-10-02; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-02 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $15.00
Why
Momentum70 · Δ7d +4.4
Value41 · Δ7d -0.1
Sentiment68 · Δ7d +2.5
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +2.5.
Contradictions & invalidation
- • FDA-requested Jeuveau promotional remediation could constrain marketing or create further compliance costs; the response and any subsequent action are not yet known. FDA letter
- • Failure to sustain Jeuveau growth, Evolysse adoption or the raised 2026 margin and revenue outlook would weaken the commercial thesis. [#SEC-8K-2026-08-05]
- • The FDA's Jeuveau promotional finding adds a current compliance overhang to GAAP losses, cash-use and execution risks.
Catalyst clock
2026-10-31
Jeuveau promotional-compliance response
Lead driver: Sentiment · See AI snapshot
Momentum
70
8% active weight
Current posture
7d trendFlat
Δ7d
+4.4
Δ21d
+0.6
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
68
45% active weight
Current posture
7d trendFlat
Δ7d
+2.5
Δ21d
-8.4
Why this grade
Composite grade C. Momentum 69.9 / Value 40.6 / Sentiment 67.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-02. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$8.00
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.30
Analysis reference price unavailable
Analysis 2026-10-02 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$463.01M
Beta
1.12
Shares Out
66.05M
P/E (TTM) · Derived
-8.8
P/S (TTM)
1.37
P/FCF (TTM) · Derived
-24.87
Rev YoY
+21.2%
EPS YoY
-54.0%
Gross Margin
+64.9%
Op Margin
-6.5%
Net Debt
$101.17M
Current Ratio
1.70
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data